Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Inceptionr LLC

Inceptionr LLC lessened its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 72.9% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 13,778 shares of the biopharmaceutical company's stock after selling 37,014 shares during the quarter. Inceptionr LLC's holdings in Amicus Therapeutics were worth $130,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Los Angeles Capital Management LLC boosted its position in shares of Amicus Therapeutics by 46.3% during the 3rd quarter. Los Angeles Capital Management LLC now owns 20,474 shares of the biopharmaceutical company's stock valued at $219,000 after acquiring an additional 6,484 shares during the last quarter. GSA Capital Partners LLP increased its holdings in shares of Amicus Therapeutics by 163.8% in the 3rd quarter. GSA Capital Partners LLP now owns 133,800 shares of the biopharmaceutical company's stock worth $1,429,000 after buying an additional 83,081 shares during the last quarter. OLD Second National Bank of Aurora bought a new stake in shares of Amicus Therapeutics in the 3rd quarter worth about $26,000. Tokio Marine Asset Management Co. Ltd. bought a new stake in shares of Amicus Therapeutics in the 3rd quarter valued at approximately $113,000. Finally, Wrapmanager Inc. bought a new position in shares of Amicus Therapeutics during the 3rd quarter valued at approximately $220,000.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on FOLD. StockNews.com downgraded shares of Amicus Therapeutics from a "buy" rating to a "hold" rating in a research note on Thursday, February 20th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. Wells Fargo & Company decreased their target price on Amicus Therapeutics from $18.00 to $17.00 and set an "overweight" rating for the company in a research report on Thursday, February 20th. Morgan Stanley reissued an "equal weight" rating and set a $12.00 target price (down from $17.00) on shares of Amicus Therapeutics in a research note on Friday, December 13th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and set a $21.00 price objective on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $16.75.

Remove Ads

Amicus Therapeutics Stock Performance

FOLD traded up $0.09 during trading on Friday, reaching $8.90. 1,804,077 shares of the company's stock were exchanged, compared to its average volume of 2,339,965. The company has a debt-to-equity ratio of 2.01, a current ratio of 3.39 and a quick ratio of 2.42. Amicus Therapeutics, Inc. has a 1 year low of $8.55 and a 1 year high of $12.65. The company's fifty day simple moving average is $9.39 and its 200-day simple moving average is $10.18. The stock has a market capitalization of $2.73 billion, a P/E ratio of -49.44, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.